Wall Street Analyst Initiated Bristol-Myers Squibb Company [BMY]. What else is Wall St. saying

Bristol-Myers Squibb Company [NYSE: BMY] stock went on a downward path that fall over -1.27% on Friday, amounting to a one-week price decrease of less than -0.82%. The company report on December 20, 2022 that Moments of Serendipity As Our Teams ‘Light the Night’.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Bristol Myers Squibb Company

Bristol Myers Squibb has a long-standing partnership with the Leukemia and Lymphoma Society (LLS) and has been the top biopharma fundraising team for Light The Night® for more than a decade. Since 1949, the LLS has invested nearly $1.5 billion in cancer research. While Light The Night is a U.S.-based event, it supports the LLS, a global leader in cancer research.

Over the last 12 months, BMY stock rose by 17.47%. The one-year Bristol-Myers Squibb Company stock forecast points to a potential upside of 10.18. The average equity rating for BMY stock is currently 2.30, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $156.97 billion, with 2.13 billion shares outstanding and 2.12 billion shares in the current float. Compared to the average trading volume of 9.47M shares, BMY stock reached a trading volume of 7029263 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Bristol-Myers Squibb Company [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $81.15 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 18, 2022. The new note on the price target was released on October 10, 2022, representing the official price target for Bristol-Myers Squibb Company stock. Previously, the target price had yet another drop from $82 to $76, while Berenberg kept a Hold rating on BMY stock.

The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.35, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.36. The Price to Book ratio for the last quarter was 4.76, with the Price to Cash per share for the same quarter was set at 4.19. Price to Free Cash Flow for BMY in the course of the last twelve months was 19.29 with Quick ratio for the last quarter at 1.30.

BMY Stock Performance Analysis:

Bristol-Myers Squibb Company [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.82. With this latest performance, BMY shares dropped by -7.90% in over the last four-week period, additionally sinking by -8.86% over the last 6 months – not to mention a rise of 17.47% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 31.37, with the RSI for the last a single of trading hit 25.35, and the three-weeks RSI is set at 37.31 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 76.61, while it was recorded at 73.17 for the last single week of trading, and 74.49 for the last 200 days.

Insight into Bristol-Myers Squibb Company Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +20.57 and a Gross Margin at +57.69. Bristol-Myers Squibb Company’s Net Margin is presently recorded at +15.08.

Return on Equity for this stock inclined to 18.96, with Return on Assets sitting at 6.14.

Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 4.14%.

Bristol-Myers Squibb Company [BMY] Insider Position Details

There are presently around $119,851 million, or 79.40% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 199,886,585, which is approximately 1.554% of the company’s market cap and around 0.07% of the total institutional ownership; BLACKROCK INC., holding 174,002,852 shares of the stock with an approximate value of $12.68 billion in BMY stocks shares; and JPMORGAN CHASE & CO, currently with $7.25 billion in BMY stock with ownership of nearly 1.778% of the company’s market capitalization.

Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,097 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 64,888,215 shares. Additionally, 1,176 investors decreased positions by around 77,017,848 shares, while 359 investors held positions by with 1,502,364,326 shares. The mentioned changes placed institutional holdings at 1,644,270,389 shares, according to the latest SEC report filing. BMY stock had 98 new institutional investments in for a total of 2,606,828 shares, while 134 institutional investors sold positions of 5,276,599 shares during the same period.


Please enter your comment!
Please enter your name here